Company Overview
Invivyd, Inc. is a biotechnology entity dedicated to the research, development, commercialization, and sale of antibody therapies designed for the prevention and treatment of viral infectious diseases within the United States. The company operates within the Healthcare sector, specifically targeting the Biotechnology industry, which implies a focus on high-risk, high-reward innovation cycles driven by clinical trial outcomes and regulatory approvals. As a mid-cap public company, Invivyd reports a market capitalization of $440.85M and generates annual revenue of $53.43M over a trailing twelve-month period. The organization employs a workforce of 122 individuals, indicating a lean operational structure typical of early-to-mid stage biopharmaceutical firms. The combination of a $440.85M market cap and $53.43M in revenue suggests the company is valued significantly above its current sales output, reflecting market expectations for future growth from its investigational monoclonal antibody pipeline, Pemivibart.
Financial Health
Invivyd reports a trailing twelve-month revenue of $53.43M, while simultaneously posting a net income loss of $52,489,000 and an EBITDA of $-54,805,000. The substantial gap between positive revenue and negative net income reveals a cost structure characterized by high operating expenses, likely driven by research and development activities, clinical trial costs, and general corporate overhead that currently exceed total revenue generation. The company's free cash flow stands at $-38,399,000, indicating a negative cash burn rate that necessitates continuous access to capital markets or cash reserves to fund ongoing operations. Analyzing the margin profile, the company maintains a gross margin of 93.0%, which suggests highly efficient manufacturing or sourcing of its antibody therapies before accounting for selling, general, and administrative costs. However, the operating margin is reported at -73.0%, and the profit margin sits at -98.2%, illustrating that overhead costs are aggressively eroding profitability as the company scales its commercial efforts. On the balance sheet, Invivyd holds $226.69M in cash against a total debt load of $2.49M, resulting in a debt-to-equity ratio of 1.03. Despite the nominal debt figure, the debt-to-equity ratio indicates a level of leverage that is atypical for a cash-rich biotech firm, though the absolute debt amount remains negligible relative to available liquidity. The current ratio of 7.24 demonstrates robust short-term liquidity, providing ample coverage for immediate obligations and operational runway. Return on Equity is calculated at -34.0%, and return on assets is -17.1%, metrics that reflect the dilutive impact of losses on shareholder value and asset utilization efficiency during the development phase of its therapies.
Valuation Assessment
The valuation metrics for Invivyd present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive net income, while the forward P/E is calculated at -39.00. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in future earnings that are not yet realized, necessitating a reliance on non-GAAP or alternative metrics to assess value. The price-to-book ratio stands at 1.82, indicating that the market values the company at a premium of 82% over its tangible book value, likely driven by the intangible value of its intellectual property and pipeline assets. Alternative valuation measures include a price-to-sales ratio of 8.25 and an EV/EBITDA of -3.95, which suggest the company is priced for significant future expansion rather than current cash flow generation. Regarding price levels, the stock has a 52-week high of $3.07 and a 52-week low of $0.46, with the current trading price situated somewhere within this volatile range relative to the established extremes. The beta value is 0.61, which indicates that the stock's price volatility is approximately 39% lower than the broader market, suggesting lower sensitivity to general market movements compared to large-cap equities.
Growth & Income
Invivyd reports a revenue growth rate of 24.5% year-over-year, while the earnings growth rate is listed as N/A due to the company's current unprofitability. Since earnings are not growing at a positive rate, the revenue expansion does not yet translate into profitability, implying that the company is still in an investment phase where sales growth is being prioritized over immediate bottom-line results. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available capital back into research, development, and commercialization rather than distributing income to shareholders. This approach aligns with the growth profile of a biotechnology firm that must fund expensive clinical trials to bring therapies like Pemivibart to market. The overall growth and income profile is defined by rapid revenue expansion without current earnings generation or dividend distribution, creating a high-risk, high-potential-return scenario dependent on the successful commercialization of its viral infectious disease treatments.